New Targets in Blood Pressure Control: Arguments Pro and Contra
https://doi.org/10.18087/cardio.2019.5.2510
Abstract
The review contains results of analysis of clinical studies on the problem of defining the target level of the blood pressure (BP). The rationale for selection the target systolic BP level below120 mmHg was obtained in the SPRINT study comparing the target levels <120 mmHg and <140 mmHg. A considerably lower number of cardiovascular complications and deaths was seen in the group of a stricter BP control. Nevertheless, this study had some limitations related to certain patient populations, and methods of BP measurement. More ambitious target of BP lowering was associated with elevated risk of iatrogenic hypotension and fainting. Moreover, the ACCORD study, exploring the same target levels failed to demonstrate similar risk reduction. Taking into account various literature data, the authors find it reasonable to use personalized approach to determining BP targets, and utilize assessment of central aortic pressure and state of vessels for more accurate risk stratification and selection of treatment.
About the Authors
O. N. Antropova
Altay State Medical University
Russian Federation
Russian Federation
Antropova Oksana N. – MD, professor
Barnaul
I. V. Osipova
Altay State Medical University
Russian Federation
Barnaul
Russian Federation
Barnaul
References
1. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C et al. 2017 ACC/AHA/AAPA/ABC/ ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):e13–115. DOI: 10.1161/HYP.0000000000000065
2. Ioannidis JPA. Diagnosis and Treatment of Hypertension in the 2017 ACC/AHA Guidelines and in the Real World. JAMA. 2018;319(2):115. DOI: 10.1001/jama.2017.19672
3. Ginsberg HN. The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid Trial: What we learn from subgroup analyses. Diabetes Care. 2011;34(Supplement_2):S107–8. DOI: 10.2337/dc11-s203
4. Egan BM, Stevens-Fabry S. Prehypertension – prevalence, health risks and management strategies. Nature Reviews Cardiology. 2015;12(5):289–300. DOI: 10.1038/nrcardio.2015.17
5. Rocco MV, Sink KM, Lovato LC, Wolfgram DF, Wiegmann TB, Wall BM et al. Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT). American Journal of Kidney Diseases. 2018;71(3):352–61. DOI: 10.1053/j.ajkd.2017.08.021
6. Dungan K, Craven TE, Soe K, Wright JT, Basile J, Haley WE et al. Influence of metabolic syndrome and race on the relationship between intensive blood pressure control and cardiovascular outcomes in the SPRINT cohort. Diabetes, Obesity and Metabolism. 2018;20(3):629–37. DOI: 10.1111/dom.13127
7. Bress AP, King JB, Kreider KE, Beddhu S, Simmons DL, Cheung AK et al. Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial. Diabetes Care. 2017;40(10):1401–8. DOI: 10.2337/dc17-0885
8. Foy CG, Lovato LC, Vitolins MZ, Bates JT, Campbell R, Cushman WC et al. Gender, blood pressure, and cardiovascular and renal outcomes in adults with hypertension from the Systolic Blood Pressure Intervention Trial: Journal of Hypertension. 2018;36(4):904–15. DOI: 10.1097/HJH.0000000000001619
9. Garofalo C, Borrelli S, Pacilio M, Minutolo R, Chiodini P, De Nicola L et al. Hypertension and Prehypertension and Prediction of Development of Decreased Estimated GFR in the General Population: A Meta-analysis of Cohort Studies. American Journal of Kidney Diseases. 2016;67(1):89–97. DOI: 10.1053/j.ajkd.2015.08.027
10. Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Annals of Internal Medicine. 2006;144(12):884–93. PMID: 16785477
11. Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R et al. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study: Journal of Hypertension. 2009;27(7):1360–9. DOI: 10.1097/HJH.0b013e32832d7370
12. Fan F, Yuan Z, Qin X, Li J, Zhang Y, Li Y et al. Optimal Systolic Blood Pressure Levels for Primary Prevention of Stroke in General Hypertensive Adults: Findings From the CSPPT (China Stroke Primary Prevention Trial). Hypertension. 2017;69(4):697–704. DOI: 10.1161/HYPERTENSIONAHA.116.08499
13. Ladeiras-Lopes R, Fontes-Carvalho R, Vilela EM, Bettencourt P, Leite-Moreira A, Azevedo A. Diastolic Function Is Impaired in Patients With Prehypertension: Data From the EPIPorto Study. Revista Espanola de Cardiologia (English Edition). 2018;71(11):926–34. DOI: 10.1016/j.rec.2017.11.015
14. Thitiwuthikiat P, Siriwittayawan D, Nuamchit T. Prehypertension and high serum uric acid increase risk of arterial stiffness. Scandinavian Journal of Clinical and Laboratory Investigation. 2017;77(8):673–8. DOI: 10.1080/00365513.2017.1397287
15. McEvoy JW, Martin SS, Dardari ZA, Miedema MD, Sandfort V, Yeboah J et al. Coronary Artery Calcium to Guide a Personalized Risk-Based Approach to Initiation and Intensification of Antihypertensive Therapy. Circulation. 2017;135(2):153–65. DOI: 10.1161/CIRCULATIONAHA.116.025471
16. Protogerou AD, Aissopou EK, Argyris A, Nasothimiou EG, Konstantonis GD, Karamanou M et al. Phenotypes of office systolic blood pressure according to both brachial and aortic measurements: frequencies and associations with carotid hypertrophy in 1861 adults. Journal of Hypertension. 2016;34(7):1325–30. DOI: 10.1097/HJH.0000000000000955
17. Chen Y-L, Hsu C-H, Hsieh C-H, Wu C-Z, Lin J-D, Chang J-B et al. High normotension is associated with future metabolic syndrome but not cardiovascular disease: A 10-year longitudinal study. Medicine. 2017;96(25):e7227. DOI: 10.1097/MD.0000000000007227
18. Hwang Y-C, Fujimoto WY, Kahn SE, Leonetti DL, Boyko EJ. Greater visceral abdominal fat is associated with a lower probability of conversion of prehypertension to normotension: Journal of Hypertension. 2017;35(6):1213–8. DOI: 10.1097/HJH.0000000000001296
19. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressurelowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials. Journal of Hypertension. 2017;35(11):2150–60. DOI: 10.1097/HJH.0000000000001547
20. Sink KM, Evans GW, Shorr RI, Bates JT, Berlowitz D, Conroy MB et al. Syncope, Hypotension, and Falls in the Treatment of Hypertension: Results from the Randomized Clinical Systolic Blood Pressure Intervention Trial: SYNCOPE, HYPOTENSION, AND FALLS IN THE SPRINT TRIAL. Journal of the American Geriatrics Society. 2018;66(4):679–86. DOI: 10.1111/jgs.15236
21. Beddhu S, Greene T, Boucher R, Cushman WC, Wei G, Stoddard G et al. Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials. The Lancet Diabetes & Endocrinology. 2018;6(7):555–63. DOI: 10.1016/S2213-8587(18)30099-8
22. Schiffrin EL, Calhoun DA, Flack JM. SPRINT Proves that Lower Is Better for Nondiabetic High-Risk Patients, but at a Price. American Journal of Hypertension. 2016;29(1):2–4. DOI: 10.1093/ajh/hpv190
23. Kjeldsen SE, Lund-Johansen P, Nilsson PM, Mancia G. Unattended Blood Pressure Measurements in the Systolic Blood Pressure Intervention Trial: Implications for Entry and Achieved Blood Pressure Values Compared With Other Trials. Hypertension. 2016;67(5):808–12. DOI: 10.1161/HYPERTENSIONAHA.116.07257
24. Parati G, Ochoa JE, Bilo G, Zanchetti A. SPRINT Blood Pressure: Sprinting Back to Smirk’s Basal Blood Pressure? Hypertension. 2017;69(1):15–9. DOI: 10.1161/HYPERTENSIONAHA.116.08216
25. Drawz PE, Pajewski NM, Bates JT, Bello NA, Cushman WC, Dwyer JP et al. Effect of Intensive Versus Standard Clinic-Based Hypertension Management on Ambulatory Blood Pressure: Results From the SPRINT (Systolic Blood Pressure Intervention Trial) Ambulatory Blood Pressure Study. Hypertension. 2017;69(1):42– 50. DOI: 10.1161/HYPERTENSIONAHA.116.08076
Review
For citations:
Antropova O.N., Osipova I.V. New Targets in Blood Pressure Control: Arguments Pro and Contra. Kardiologiia. 2019;59(5):87-91. (In Russ.) https://doi.org/10.18087/cardio.2019.5.2510
Views:
1142
Email this article 
Post a Comment 
